LGND Ligand Pharmaceuticals PE ratio, current and historical analysis
The current PE ratio of LGND can't be determined, as the TTM EPS of -$0.22 is negative. The last PE ratio of Ligand Pharmaceuticals, recorded in September 2024, was 37.91.
LGND PE ratio history
The PE ratio of Ligand Pharmaceuticals has averaged 85.6 over the last ten years. Over the past ten years, LGND's PE ratio was at its highest in the Sep 2020 quarter at 794.33, when the stock price was $95.32 and the EPS was $0.12. The lowest value was in the Dec 2019 quarter, when it reached 3.15 with a price of $104.29 and an EPS of $33.13.
Ligand Pharmaceuticals PE ratio by year
Maximum annual decrease: -91.22% in 2018
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $107.15 | -$0.22 |
| 2023 | 23.65 | N/A | $71.42 | $3.02 |
| 2022 | N/A | N/A | $66.8 | -$1.98 |
| 2021 | 44.9 | N/A | $154.46 | $3.44 |
| 2020 | N/A | N/A | $99.45 | -$0.18 |
| 2019 | 3.15 | -84.28% | $104.29 | $33.13 |
| 2018 | 20.04 | -91.22% | $135.7 | $6.77 |
| 2017 | 228.22 | N/A | $136.93 | $0.6 |
| 2016 | N/A | N/A | $101.61 | -$0.08 |
| 2015 | 9.34 | -89.64% | $108.42 | $11.61 |
| 2014 | 90.19 | -3.98% | $53.21 | $0.59 |
| 2013 | 93.93 | N/A | $52.6 | $0.56 |
| 2012 | N/A | N/A | $20.74 | -$0.03 |
| 2011 | 24.22 | N/A | $11.87 | $0.49 |
| 2010 | N/A | N/A | $8.92 | -$0.53 |
Ligand Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | N/A | N/A | $107.15 | -$0.22 |
| Sep 2024 | 37.91 | 9.79% | $100.09 | $2.64 |
| Jun 2024 | 34.53 | 157.49% | $84.26 | $2.44 |
| Mar 2024 | 13.41 | -43.3% | $73.1 | $5.45 |
| Dec 2023 | 23.65 | -62.11% | $71.42 | $3.02 |
| Sep 2023 | 62.42 | 35.93% | $59.92 | $0.96 |
| Jun 2023 | 45.92 | -13.23% | $72.1 | $1.57 |
| Mar 2023 | 52.92 | N/A | $73.56 | $1.39 |
| Dec 2022 | N/A | N/A | $66.8 | -$1.98 |
| Sep 2022 | N/A | N/A | $86.11 | -$1.27 |
| Jun 2022 | N/A | N/A | $89.22 | -$0.47 |
| Mar 2022 | 79.22 | 76.44% | $112.49 | $1.42 |
| Dec 2021 | 44.9 | 32.76% | $154.46 | $3.44 |
| Sep 2021 | 33.82 | -25.75% | $139.32 | $4.12 |
| Jun 2021 | 45.55 | -27.7% | $131.19 | $2.88 |
LGND average PE ratio chart
LGND PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| MRK Merck & Co Inc | 12.59 | $214.97B |
| PFE Pfizer Inc | 16.87 | $135.79B |
| JNJ Johnson & Johnson | 17.29 | $376.98B |
| BMY Bristol Myers Squibb Co | 18.42 | $100.47B |
| AMGN Amgen Inc | 37.87 | $155.02B |
| LLY ELI LILLY & Co | 75.09 | $837.23B |
| BAX Baxter International Inc | N/A | $15.85B |
| LGND Ligand Pharmaceuticals Inc | N/A | $2.14B |
Frequently asked questions
What is Ligand Pharmaceuticals's PE ratio?
The current price to earnings ratio of LGND can't be calculated, as its EPS of -$0.22 is negative.
What is the 3-year average PE ratio for Ligand Pharmaceuticals (LGND)?
The 3-year average PE ratio for LGND stock is 38.68.
What is the 5-year average PE ratio for Ligand Pharmaceuticals (LGND)?
The 5-year average PE ratio for LGND stock is 102.43.
What is the highest PE ratio for LGND?
The highest quarterly PE ratio in the last ten years has been 794.33 and it was in the Sep 2020 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.